Literature DB >> 27452791

An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Tiago V Maia1, Michael J Frank2.   

Abstract

We propose that schizophrenia involves a combination of decreased phasic dopamine responses for relevant stimuli and increased spontaneous phasic dopamine release. Using insights from computational reinforcement-learning models and basic-science studies of the dopamine system, we show that each of these two disturbances contributes to a specific symptom domain and explains a large set of experimental findings associated with that domain. Reduced phasic responses for relevant stimuli help to explain negative symptoms and provide a unified explanation for the following experimental findings in schizophrenia, most of which have been shown to correlate with negative symptoms: reduced learning from rewards; blunted activation of the ventral striatum, midbrain, and other limbic regions for rewards and positive prediction errors; blunted activation of the ventral striatum during reward anticipation; blunted autonomic responding for relevant stimuli; blunted neural activation for aversive outcomes and aversive prediction errors; reduced willingness to expend effort for rewards; and psychomotor slowing. Increased spontaneous phasic dopamine release helps to explain positive symptoms and provides a unified explanation for the following experimental findings in schizophrenia, most of which have been shown to correlate with positive symptoms: aberrant learning for neutral cues (assessed with behavioral and autonomic responses), and aberrant, increased activation of the ventral striatum, midbrain, and other limbic regions for neutral cues, neutral outcomes, and neutral prediction errors. Taken together, then, these two disturbances explain many findings in schizophrenia. We review evidence supporting their co-occurrence and consider their differential implications for the treatment of positive and negative symptoms.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computational psychiatry; Dopamine; Negative symptoms; Prediction error; Psychosis; Reinforcement learning; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27452791      PMCID: PMC5486232          DOI: 10.1016/j.biopsych.2016.05.021

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  144 in total

Review 1.  Phasic dopamine release in appetitive behaviors and drug addiction.

Authors:  Matthew J Wanat; Ingo Willuhn; Jeremy J Clark; Paul E M Phillips
Journal:  Curr Drug Abuse Rev       Date:  2009-05

2.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

3.  Working memory contributions to reinforcement learning impairments in schizophrenia.

Authors:  Anne G E Collins; Jaime K Brown; James M Gold; James A Waltz; Michael J Frank
Journal:  J Neurosci       Date:  2014-10-08       Impact factor: 6.167

4.  A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol.

Authors:  Michael J Frank; Randall C O'Reilly
Journal:  Behav Neurosci       Date:  2006-06       Impact factor: 1.912

5.  Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes.

Authors:  Stefano Palminteri; Maël Lebreton; Yulia Worbe; David Grabli; Andreas Hartmann; Mathias Pessiglione
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-22       Impact factor: 11.205

Review 6.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 7.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

Review 8.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

9.  Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety.

Authors:  Larry S Zweifel; Jonathan P Fadok; Emmanuela Argilli; Michael G Garelick; Graham L Jones; Tavis M K Dickerson; James M Allen; Sheri J Y Mizumori; Antonello Bonci; Richard D Palmiter
Journal:  Nat Neurosci       Date:  2011-04-17       Impact factor: 24.884

10.  The computational anatomy of psychosis.

Authors:  Rick A Adams; Klaas Enno Stephan; Harriet R Brown; Christopher D Frith; Karl J Friston
Journal:  Front Psychiatry       Date:  2013-05-30       Impact factor: 4.157

View more
  63 in total

1.  Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia.

Authors:  Michael Davidson
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

2.  Nucleus accumbens activation is linked to salience in social decision making.

Authors:  Stephanie N L Schmidt; Sabrina C Fenske; Peter Kirsch; Daniela Mier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10-25       Impact factor: 5.270

3.  Cerebral blood flow in striatal regions is associated with apathy in patients with schizophrenia.

Authors:  Karoline Schneider; Lars Michels; Matthias N Hartmann-Riemer; Achim Burrer; Philippe N Tobler; Philipp Stämpfli; Matthias Kirschner; Erich Seifritz; Stefan Kaiser
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

4.  Age-Normative Pathways of Striatal Connectivity Related to Clinical Symptoms in the General Population.

Authors:  Anita D Barber; Deepak K Sarpal; Majnu John; Christina L Fales; Stewart H Mostofsky; Anil K Malhotra; Katherine H Karlsgodt; Todd Lencz
Journal:  Biol Psychiatry       Date:  2019-02-06       Impact factor: 13.382

5.  Meta-analytic evidence for altered mesolimbic responses to reward in schizophrenia.

Authors:  Henry W Chase; Polina Loriemi; Tobias Wensing; Simon B Eickhoff; Thomas Nickl-Jockschat
Journal:  Hum Brain Mapp       Date:  2018-03-24       Impact factor: 5.038

Review 6.  Dopamine: Functions, Signaling, and Association with Neurological Diseases.

Authors:  Marianne O Klein; Daniella S Battagello; Ariel R Cardoso; David N Hauser; Jackson C Bittencourt; Ricardo G Correa
Journal:  Cell Mol Neurobiol       Date:  2018-11-16       Impact factor: 5.046

7.  Altered Coupling Between Resting-State Cerebral Blood Flow and Functional Connectivity in Schizophrenia.

Authors:  Jiajia Zhu; Chuanjun Zhuo; Lixue Xu; Feng Liu; Wen Qin; Chunshui Yu
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

8.  A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine.

Authors:  Clifford M Cassidy; Peter D Balsam; Jodi J Weinstein; Rachel J Rosengard; Mark Slifstein; Nathaniel D Daw; Anissa Abi-Dargham; Guillermo Horga
Journal:  Curr Biol       Date:  2018-02-02       Impact factor: 10.834

9.  Cognitive Enhancing Effect of High-Frequency Neuronavigated rTMS in Chronic Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind Controlled 32-Week Follow-up Study.

Authors:  Mei Hong Xiu; Heng Yong Guan; Jian Min Zhao; Ke Qiang Wang; Yan Fen Pan; Xiu Ru Su; Yu Hong Wang; Jin Ming Guo; Long Jiang; Hong Yu Liu; Shi Guang Sun; Hao Ran Wu; Han Song Geng; Xiao Wen Liu; Hui Jing Yu; Bao Chun Wei; Xi Po Li; Tammy Trinh; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-03-17       Impact factor: 9.306

10.  Impaired Expected Value Computations in Schizophrenia Are Associated With a Reduced Ability to Integrate Reward Probability and Magnitude of Recent Outcomes.

Authors:  Dennis Hernaus; Michael J Frank; Elliot C Brown; Jaime K Brown; James M Gold; James A Waltz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.